Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series.

Garweg, Justus G; Traine, Peter G; Garweg, Richard A; Wons, Juliana; Gerhardt, Christin; Pfister, Isabel B (2022). Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series. Eye, 36(4), pp. 862-868. Springer Nature 10.1038/s41433-021-01562-6

[img]
Preview
Text
s41433-021-01562-6.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (629kB) | Preview

BACKGROUND

The continuation of anti-vascular endothelial growth factor (anti-VEGF) treatment after achieving stability in patients with neovascular age-related macular degeneration has generally been advocated. In our own patients, we thought to assess whether continued anti-VEGF treatment is capable of preventing recurrences.

METHODS

In this retrospective observational case series, patients with stable disease either opted to continue treatment every 12-14 weeks (Group 1) or stopped treatment with subsequent follow-up visits every 8-12 weeks (Group 2).

RESULTS

Of the 103 eyes of 103 patients achieving stability, 49 eyes continued treatment (Group 1), whereas treatment was stopped in 54 eyes undergoing regular follow-up (Group 2). Recurrent disease was observed in 21 (42.9%) and 33 (61.1%) cases in Group 1 and Group 2, respectively (p = 0.08). Time between achieving stable disease and recurrence was comparable between Group 1 and Group 2 (11.1 ± 8.2 months vs. 9.2 ± 6.7 months; p = 0.43). The number of visits between achieving stability and disease recurrence was similar, but not the number of injections (3.5 ± 2.0 vs. 0.2 ± 0.4; p < 0.001).

CONCLUSIONS

Continuing anti-VEGF therapy after achieving functional and morphological stability every 12-14 weeks does not prevent recurrences. Patients deserve to be informed of a potential lifetime risk of recurrences, even under continued therapy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Garweg, Justus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1476-5454

Publisher:

Springer Nature

Language:

English

Submitter:

Sebastian Wolf

Date Deposited:

19 Jan 2022 07:25

Last Modified:

05 Dec 2022 15:58

Publisher DOI:

10.1038/s41433-021-01562-6

PubMed ID:

33941877

BORIS DOI:

10.48350/162743

URI:

https://boris.unibe.ch/id/eprint/162743

Actions (login required)

Edit item Edit item
Provide Feedback